DDDebora D'ANiello

Debora D'ANiello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Debora D'ANiello has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Giorgia Perniola

    Department of Maternal and Child Health and Urological Sciences, Umberto I Hospital, Sapienza University, Rome, Italy

    2 shared publications
  • Innocenza Palaia

    Department of Maternal and Child Health and Urological Sciences, Umberto I Hospital, Sapienza University, Rome, Italy

    2 shared publications
  • Pierluigi Benedetti Panici

    Department of Maternal and Child Health and Urological Sciences, Umberto I Hospital, Sapienza University, Rome, Italy

    2 shared publications
  • Violante Di Donato

    Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy

    2 shared publications
  • Andrea Giannini

    Unit of Gynecology, Sant’Andrea Hospital, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, 00189 Rome, Italy

    1 shared publication
  • Angela Musella

    Department of Maternal and Child Health and Urological Sciences, University of Rome "Sapienza," Umberto I Hospital, Rome, Italy

    1 shared publication

Latest Publications

  • Open Access

    Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study

    by Innocenza Palaia, Giuseppe Caruso, Violante Di Donato, Annarita Vestri, Anna Napoli, Giorgia Perniola, Matteo Casinelli, Danilo Alunni Fegatelli, Roberta Campagna, Federica Tomao, et al.

    Objective: To evaluate the safety and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in gynecologic oncology patients under chemotherapy. Methods: A prospective cohort study including gynecologic oncology women who were under chemotherapy or had completed it within 6 months at the time of the study. All patients received a two-dose schedule of the Pfizer-BioNTech COVID-19 vaccine. Results were compared with a control group of healthy women vaccinated in the same period. Results: Overall, 44 oncologic patients with a mean age of 61.3 ± 10.7 years were enrolled: 28 (63.6%) had ovarian cancer, 9 (20.4%) endometrial, and 7 (16%) cervical. The IgG antibody titer after 1 month from vaccination was low in 9 (20.5%) patients, moderate in 21 (47.7%), and high in 14 (31.8%). The 3-month titer was null in 2 (4.5%) patients, low in 26 (59.1%), moderate in 13 (29.5%), and high in 3 (6.8%). Patients ≥ 50 years reported lower 1-month (p = 0.018) and 3-month (p = 0.004) titers compared with 2 had a higher 1-month titer compared with BMI ≥ 30 kg/m2 (p = 0.016). Compared with healthy women (n = 44), oncologic patients showed a lower 3-month titer (p < 0.001). None of the patients experienced serious adverse effects. Conclusions: The COVID-19 vaccine was safe and immunogenic in gynecologic oncology patients under chemotherapy. Serological monitoring and further vaccine shots should be considered to boost protection.


  • Relationship between cervical excisional treatment for cervical intraepithelial neoplasia and obstetrical outcome

    by Marco Monti, Debora D’aNiello, Annalisa Scopelliti, Valentina Tibaldi, Giusi Santangelo, Vanessa Colagiovanni, Andrea Giannini, Violante DI Donato, Innocenza Palaia, Giorgia Perniola, et al.

    Article: Relationship between cervical excisional treatment for cervical intraepithelial neoplasia and obstetrical outcome - Minerva Obstetrics and Gynecology 2021 April;73(2):233-46 - Minerva Medica - Journals


  • Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review

    by Violante Di Donato, Innocenza Palaia, Debora D'ANiello, Lucia Musacchio, Giusi Santangelo, Federica Di Mauro, Anna Di Pinto, Angela Musella, Margherita Fischetti, Federica Tomao, et al.

    Purpose: The objective of this study was to evaluate the impact of hormone replacement therapy (HRT) on the prognosis in endometrial cancer (EC) survivors. Methods: The research was conducted using the following electronic databases: MEDLINE (PubMed), Web of Science, ClinicalTrial.gov, and Cochrane Library. We performed a review of studies published from January 1986 to January 2019. We selected studies that included EC patients submitted to surgery with curative intent and postoperative use of HRT. Result: Seven of 1,332 abstracts considered were eligible: 4 retrospective series, 1 prospective study, 1 randomized controlled trial, and 1 population study. Globally in the observed studies there was not a significant increase in the recurrence rate, measured by the relative risk, in the EC survivors using HRT compared with the controls in tumour stages I and II. The bias was that HRT was prescribed only to low-risk patients, who were young and had a low stage of disease. Conclusion: This systematic review shows that HRT use had no negative effect on prognosis in EC survivors in tumour stages I and II.